MedTrace Logo

A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

NCT06025110 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-08-14

No results posted yet for this study

Summary

The goal of this study is to determine if treatment with TCD601 improves beta-cell function in adults recently diagnosed with type 1 diabetes compared to placebo.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

BIOLOGICAL

TCD601

Investigational Product

OTHER

Placebo

Comparator

Sponsors & Collaborators

  • ITB-Med LLC

    lead INDUSTRY

Principal Investigators

  • Fredrik Juhlin · ITB-MED

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-23
Primary Completion
2025-07-24
Completion
2025-07-24

Countries

  • Belgium
  • Italy
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06025110 on ClinicalTrials.gov